Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.


The opportunity for greater patient and public involvement and engagement in drug development and regulation

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout

Nature Reviews Drug Discovery 22, 337-338 (2023)



O.L.A. receives funding from the National Institute for Health and Care Research (NIHR) Birmingham Biomedical Research Centre (BRC), the NIHR Applied Research Collaboration (ARC), NIHR Birmingham-Oxford Blood and Transplant Research Unit (BTRU) in Precision Transplant and Cellular Therapeutics, at the University of Birmingham and University Hospitals Birmingham NHS Foundation, Innovate UK (part of UK Research and Innovation), Gilead Sciences, Merck and Sarcoma UK. S.C.R. receives funding from Merck, UK SPINE, and European Regional Development Fund – Demand Hub. M.J.C. receives funding from NIHR BRC, NIHR BTRU, the NIHR Surgical Reconstruction and Microbiology Research Centre and NIHR ARC West Midlands, UK SPINE, European Regional Development Fund – Demand Hub, Health Data Research UK at the University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Innovate UK (part of UK Research and Innovation), Macmillan Cancer Support, UCB Pharma, GSK, and Gilead Sciences. The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of the regulatory agencies or organizations with which the authors are employed/affiliated.


  1. Aiyegbusi, O. L. et al. Patient and public perspectives on cell and gene therapies: a systematic review. Nat. Commun. 11, 6265 (2020).

    Article  PubMed  Google Scholar 

  2. Beauchamp, T. L. & Childress, J. F. Principles of Biomedical Ethics (Oxford Univ. Press, 2001).

    Google Scholar 

  3. Turner, G., Aiyegbusi, O. L., Price, G. Skrybant, M. & Calvert, M. Moving beyond project-specific patient and public involvement in research. J. R. Soc. Med. 113, 16–23 (2020).

    Article  PubMed  Google Scholar 

  4. Calvert, M. J. et al. Advancing UK regulatory science and innovation in healthcare. J. R. Soc. Med. 114, 5–11 (2021).

    Article  PubMed  Google Scholar 

Download references

Supplementary Information

  1. Supplementary information

Competing Interests

O.L.A. declares personal fees from Gilead Sciences, Merck and GSK outside the submitted work. S.C.R. declares personal fees from Merck. M.J.C. received personal fees from Astellas, Aparito, CIS Oncology, Takeda, Merck, Daiichi Sankyo, Glaukos, GSK and the Patient-Centered Outcomes Research Institute outside the submitted work. In addition, a family member of M.J.C. owns shares in GSK. All other authors declare no competing interests.

Nature Careers


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing


Quick links